Mersana Therapeutics (FRA:0M4) Other Long Term Assets : €0.44 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Other Long Term Assets?

Mersana Therapeutics's other long-term assets for the quarter that ended in Dec. 2023 was €0.44 Mil.

Mersana Therapeutics's quarterly other long-term assets declined from Jun. 2023 (€0.48 Mil) to Sep. 2023 (€0.45 Mil) but then stayed the same from Sep. 2023 (€0.45 Mil) to Dec. 2023 (€0.44 Mil).

Mersana Therapeutics's annual other long-term assets declined from Dec. 2021 (€2.08 Mil) to Dec. 2022 (€0.62 Mil) and declined from Dec. 2022 (€0.62 Mil) to Dec. 2023 (€0.44 Mil).

Mersana Therapeutics Other Long Term Assets Historical Data

The historical data trend for Mersana Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Other Long Term Assets Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

Get a 7-Day Free Trial

1.31

1.77

2.08

0.62

0.44

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long Term Assets	Get a 7-Day Free Trial															0.62	0.55	0.48	0.45	0.44

Mersana Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Mersana Therapeutics (FRA:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (FRA:0M4) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

MRSN:USA

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (FRA:0M4) Headlines

No Headlines